Author: Bolysbek Dana
Editor: Kigbaeva Kamila
DestinyPharma is focused on developing new therapies for nosocomial infections to address the global threat of antimicrobial resistance. This antibiotic acts very quickly and, in this way, targets bacteria, including antibiotic-resistant strains, and also helps the bacteria lose their ability to develop resistance.
XF-73 is currently being studied in a multicenter, randomized, blind and placebo-controlled phase IIb trial for the prevention of postoperative bacterial infections, including Staphylococcus aureus. The Independent Data Monitoring Committee (IDMC), after analyzing test data on the first 75 patients undergoing heart surgery, concluded that the drug was safe.
“We are very pleased that IDMC has concluded that there are currently no safety concerns for patients treated in the Phase IIb study and that the study can continue as planned. This is consistent with our previous experience with XF-73 testing in several clinical trials, ”said Neil Clark, CEO of DestinyPharma.
XF-73 is a synthetic derivative of porphyrin (iron-free precursor of heme). This substance is an antimicrobial agent that weakens the cell walls of bacteria, violates their permeability and integrity. The antibiotic is active in the treatment of methicillin-resistant Staphylococcus aureus. Moreover, its effect is manifested in 5 minutes. It even kills bacteria in resistant biofilms. The study is expected to be completed by the end of 2020.
Source: http://www.pharmatimes.com/news/destiny_pharmas_novel_antibiotic_asset_c...
